Largest Chinese CRO, WuXi PharmaTech Co., Ltd., Purchases Multiyear ADMET Predictor License

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that WuXi PharmaTech (NYSE:WX), China’s largest contract research organization (CRO), has obtained a multiyear license to ADMET Predictor™, Simulations Plus’ flagship structure-to-property prediction software.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC